4//SEC Filing
Warren Russell F JR 4
Accession 0001104659-09-003346
CIK 0000883697other
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 9:07 PM ET
Size
16.7 KB
Accession
0001104659-09-003346
Insider Transaction Report
Form 4
Warren Russell F JR
10% Owner
Transactions
- Purchase
Warrant
2009-01-16+42,858→ 42,858 total(indirect: Held by Ivy Healthcare Capital II, L.P.)Exercise: $1.20From: 2009-01-16Exp: 2014-01-16→ Common Stock (42,858 underlying) - Purchase
Common Stock
2009-01-16$3.50/sh+285,715$1,000,003→ 812,060 total(indirect: Held by Ivy Healthcare Capital II, L.P.) - Conversion
Convertible Note
2009-01-16$500000.00/sh→ 0 total(indirect: Held by Ivy Healthcare Capital II, L.P.)Exercise: $3.00From: 2008-07-24Exp: 2009-07-24→ Common Stock (173,223 underlying) - Conversion
Common Stock
2009-01-16$3.00/sh+206,882$620,646→ 1,018,942 total(indirect: Held by Ivy Healthcare Capital II, L.P.) - Conversion
Convertible Note
2009-01-16$100000.00/sh→ 0 total(indirect: Held by Ivy Healthcare Capital II, L.P.)Exercise: $3.00From: 2008-12-04Exp: 2009-07-24→ Common Stock (33,659 underlying)
Holdings
- 27,500
Common Stock
Footnotes (6)
- [F1]The reported securities are held by Ivy Healthcare Capital II, L.P. Russell F. Warren, Jr., principal of Ivy Healthcare Capital II, L.P., has shared voting and dispositve control of the reported securities. Mr. Warren disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]Represents the number of shares issued upon conversion of convertible notes at $3.00 per share and such conversion amount included the principal amount and any accrued and unpaid interest on the notes. Some convertible notes were originally convertible at $0.15 per share, but the conversion price increased to $3.00 per share after the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F3]Such conversion price was increased from $0.15 to $3.00 per share following the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F4]Represents the principal amount of the convertible notes purchased and does not include any accrued and unpaid interest on the notes.
- [F5]Represents the number of shares of common stock into which the notes are convertible and such conversion amount includes the principal amount and any accrued and unpaid interest on the notes.
- [F6]The warrants were issued pursuant to a Subscription Agreement, dated January 16, 2009, by and between ReGen Biologics, Inc. (the "Company") and each of the investors named therein (the "Subscription Agreement"). Each investor subscribed to acquire common stock of the Company at $3.50 per share and without additional consideration, the Company provided 15% warrant coverage to each investor exercisable for additional shares of common stock.
Documents
Issuer
REGEN BIOLOGICS INC
CIK 0000883697
Entity typeother
Related Parties
1- filerCIK 0001413434
Filing Metadata
- Form type
- 4
- Filed
- Jan 20, 7:00 PM ET
- Accepted
- Jan 21, 9:07 PM ET
- Size
- 16.7 KB